Key result
The risk-benefit ratio of the live attenuated oral polio vaccine is shifting due to vaccine-associated paralytic polio, prompting consideration for a change in immunization strategy.
Design
Editorial
Authors
Loading...
This commentary discusses the risk-benefit ratio of continuing oral polio vaccine use given the occurrence of vaccine-associated paralytic polio in countries that have achieved effective control.
This commentary discusses the risk-benefit ratio of continuing oral polio vaccine use given the occurrence of vaccine-associated paralytic polio in countries that have achieved effective control.
Finn et al. (1998) conducted an editorial in Polio. Live attenuated trivalent oral (Sabin) polio vaccine (OPV) was evaluated. The risk-benefit ratio of the live attenuated oral polio vaccine is shifting due to vaccine-associated paralytic polio, prompting consideration for a change in immunization strategy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: